|
WO2019232214A1
|
|
Methods of using napabucasin
|
|
US2018333385A1
|
|
Methods for treating cancer
|
|
WO2018183089A1
|
|
Compositions for treating and/or preventing cancer
|
|
WO2018160887A1
|
|
Pdl1-specific and beta-catenin-specific asymmetric interfering rna compositions, uses or preparation thereof
|
|
WO2018102427A1
|
|
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
US2019375723A1
|
|
New Naphtho[2,3-B]Furan Derivatives
|
|
WO2018005444A2
|
|
Methods for treating cancer
|
|
WO2017160978A1
|
|
Cell cultures and use thereof
|
|
CN109069469A
|
|
The method for the treatment of cancer
|
|
WO2017100127A1
|
|
ASYMMETRIC INTERFERING RNAs, AND COMPOSITIONS, USE, OR PREPARATION THEREOF
|
|
WO2017023866A1
|
|
Method of targeting stat3 and other non-druggable proteins
|
|
MX2017015618A
|
|
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer.
|
|
KR20170141716A
|
|
Methods for treating cancer using STAT3 pathway inhibitors and kinase inhibitors
|
|
AU2016249157A1
|
|
Methods for treating cancer
|
|
CA2983010A1
|
|
Methods for treating cancer
|
|
AU2016249158A1
|
|
Methods for treating cancer
|
|
CA2980845A1
|
|
Water-soluble prodrugs
|
|
AU2015218436A1
|
|
Novel Methods For Targeting Cancer Stem Cells
|
|
EP3127907A1
|
|
New tricyclic quinone derivative
|
|
BR112016017680A2
|
|
asymmetric interference mRNA compositions that silence k-ras and methods of using them
|
